Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1

NCT02457650 is registered in ClinicalTrials.gov with Shenzhen Second People's Hospital as lead sponsor.

NCT NCT02457650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02457650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1
Lead sponsor
Shenzhen Second People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2015
Completion date
December 31, 2019
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, breast cancer, esophagus carcinoma, lung cancer, melanoma, multiple myeloma, neuroblastoma, other metastatic solid cancers, ovarian cancer, synovial sarcoma